In summary, the essential contraindications for ubrogepant include hypersensitivity to the drug, severe hepatic impairment, concurrent use of potent CYP3A4 inhibitors, pregnancy or breastfeeding, and uncontrolled hypertension. This evidence concerns the gene CYP3A4 and hypertensive disorder.